Publications

A full-list of publications is available at: https://pubmed.ncbi.nlm.nih.gov/?term=hadri+L

 

2022

Emerging Role of Exosomal Long Non-coding RNAs in Spaceflight-Associated Risks in Astronauts. Bisserier M, Saffran N, Brojakowska A, Sebastian A, Evans AC, Coleman MA, Walsh K, Mills PJ, Garikipati VNS, Arakelyan A, Hadri L*, Goukassian DA*. Front Genet. 2022 Jan 17;12:812188.

2021

Cell-Free Mitochondrial DNA as a Potential Biomarker for Astronauts’ Health. Bisserier M, Shanmughapriya S, Rai AK, Gonzalez C, Brojakowska A, Garikipati VNS, Madesh M, Mills PJ, Walsh K, Arakelyan A, Kishore R, Hadri L, Goukassian DA. J Am Heart Assoc. 2021 Nov 2;10(21):e022055. doi: 10.1161/JAHA.121.022055. Epub 2021 Oct 20.

Right predominant electrical remodeling in a pure model of pulmonary hypertension promotes reentrant arrhythmias. Strauss B, Bisserier M, Obus E, Katz MG, Fargnoli A, Cacheux M, Akar JG, Hummel JP, Hadri L, Sassi Y, Akar FG. Heart Rhythm. 2021 Sep 23:S1547-5271(21)02195-0. doi: 10.1016/j.hrthm.2021.09.021. Online ahead of print.

Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Bisserier M, Katz MG, Bueno-Beti C, Brojakowska A, Zhang S, Gubara S, Kohlbrenner E, Fazal S, Fargnoli A, Dorfmuller P, Humbert M, Hata A, Goukassian DA, Sassi Y, Hadri L. Int J Mol Sci. 2021 Aug 24;22(17):9105. doi: 10.3390/ijms22179105.

Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension
Bisserier M, Mathiyalagan P, Zhang S, Elmastour F, Dorfmüller P, Humbert M, David G, Tarzami S, Weber T, Perros F, Sassi Y, Sahoo S, Hadri L. Circulation. 2021 Jul 6;144(1):52-73. doi: 10.1161/CIRCULATIONAHA.120.047978. Epub 2021 Jun 3.

Retrospective analysis of demographic factors in COVID-19 patients entering the Mount Sinai Health System. Eskandari A, Brojakowska A, Bisserier M, Bander J, Garikipati VNS, Hadri L, Goukassian D, Fish K. PLoS One. 2021 Jul 16;16(7):e0254707. doi: 10.1371/journal.pone.0254707. eCollection 2021. PMID: 34270621

Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients. Brojakowska A, Eskandari A, Bisserier M, Bander J, Garikipati VNS, Hadri L, Goukassian DA, Fish KM. PLoS One. 2021 Jul 6;16(7):e0253660. doi: 10.1371/journal.pone.0253660. eCollection 2021. PMID: 34228746

Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. Hamouche W, Bisserier M, Brojakowska A, Eskandari A, Fish K, Goukassian DA, Hadri L. J Mol Cell Cardiol. 2021 Apr;153:72-85. PMID: 33373644 

Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension. Fazal S, Bisserier M, Hadri L. Cells. 2021 Mar 13;10(3):638. doi: 10.3390/cells10030638. PMID: 33805595

Long-Term Effects of Very Low Dose Particle Radiation on Gene Expression in the Heart: Degenerative Disease Risks. Garikipati VNS, Arakelyan A, Blakely EA, Chang PY, Truongcao MM, Cimini M, Malaredy V, Bajpai A, Addya S, Bisserier M, Brojakowska A, Eskandari A, Khlgatian MK, Hadri L, Fish KM, Kishore R, Goukassian DA. Cells. 2021 Feb 13;10(2):387. doi: 10.3390/cells10020387. PMID: 33668521

2020

Lung-targeted SERCA2a Gene Therapy: From Discovery to Therapeutic Application in Bleomycin-Induced Pulmonary Fibrosis. Bisserier M, Hadri L. J Cell Immunol. 2020;2(4):149-156. Epub 2020 May 6. PMID: 32587955

Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease.  Bisserier M, Janostiak R, Lezoualc’h F, Hadri L. Vasc Biol. 2020 Jan;2(1):R17-R34. doi: 10.1530/vb-19-0030. Epub 2020 Jan 9. PMID: 32161845

AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis. Bisserier M, Milara J, Abdeldjebbar Y, Gubara S, Jones C, Bueno-Beti C, Chepurko E, Kohlbrenner E, Katz MG, Tarzami S, Cortijo J, Leopold J, Hajjar RJ, Sassi Y, Hadri L. Mol Ther. 2020 Feb 5;28(2):394-410. doi: 10.1016/j.ymthe.2019.11.027. Epub 2019 Dec 6. PMID: 31879190

A novel secreted-cAMP pathway inhibits pulmonary hypertension via a feed-forward mechanism. Jones C, Bisserier M, Bueno-Beti C, Bonnet G, Neves-Zaph S, Lee SY, Milara J, Dorfmüller P, Humbert M, Leopold JA, Hadri L, Hajjar RJ, Sassi Y. Cardiovasc Res. 2020 Jul 1;116(8):1500-1513. doi: 10.1093/cvr/cvz244. PMID: 31529026

Current and emerging therapeutic approaches to pulmonary hypertension. Bisserier M, Pradhan N, Hadri L. Rev Cardiovasc Med. 2020 Jun 30;21(2):163-179. doi: 10.31083/j.rcm.2020.02.597. PMID: 32706206

2019

Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension.Strauss B, Sassi Y, Bueno-Beti C, Ilkan Z, Raad N, Cacheux M, Bisserier M, Turnbull IC, Kohlbrenner E, Hajjar RJ, Hadri L, Akar FG.J Mol Cell Cardiol. 2019 Feb;127:20-30. doi: 10.1016/j.yjmcc.2018.11.017. Epub 2018 Nov 28.

CXCR4 Cardiac Specific Knockout Mice Develop a Progressive Cardiomyopathy. LaRocca TJ, Altman P, Jarrah AA, Gordon R, Wang E, Hadri L, Burke MW, Haddad GE, Hajjar RJ, Tarzami ST. Int J Mol Sci. 2019 May 8;20(9):2267. doi: 10.3390/ijms20092267. PMID: 3107192

2018

Safety and long-term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension.Watanabe S, Ishikawa K, Plataki M, Bikou O, Kohlbrenner E, Aguero J, Hadri L, Zarragoikoetxea I, Fish K, Leopold JA, Hajjar RJ.Pulm Circ. 2018 Oct-Dec;8(4):2045894018799738. doi: 10.1177/2045894018799738. Epub 2018 Aug 21.

Direct measurement of left atrial and pulmonary artery pressure in rats with pulmonary hypertension.Katz MG, Fargnoli AS, Sassi Y, Hajjar RJ, Hadri L.J Thorac Cardiovasc Surg. 2018 Sep;156(3):1161-1163. doi: 10.1016/j.jtcvs.2018.05.026.

The Sugen 5416/Hypoxia Mouse Model of Pulmonary Arterial Hypertension.Bueno-Beti C, Hadri L, Hajjar RJ, Sassi Y.Methods Mol Biol. 2018;1816:243-252. doi: 10.1007/978-1-4939-8597-5_19.

Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration.Bueno-Beti C, Sassi Y, Hajjar RJ, Hadri L. Methods Mol Biol. 2018;1816:233-241. doi: 10.1007/978-1-4939-8597-5_18.

Pulmonary hypertension arising from left heart disease causes intrapulmonary venous arterialization in rats.Katz MG, Fargnoli AS, Hajjar RJ, Hadri L. J Thorac Cardiovasc Surg. 2018 Jan;155(1):281-282. doi: 10.1016/j.jtcvs.2017.08.028.

2017

CXCR4 and CXCR7 play distinct roles in cardiac lineage specification and pharmacologic β-adrenergic response.Ceholski DK, Turnbull IC, Pothula V, Lecce L, Jarrah AA, Kho C, Lee A, Hadri L, Costa KD, Hajjar RJ, Tarzami ST.Stem Cell Res. 2017 Aug;23:77-86. doi: 10.1016/j.scr.2017.06.015. Epub 2017 Jul 8.

Corrigendum: Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability.Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, d’Escamard V, Li JR, Hadri L, Fujitani K, Moreno PR, Benard L, Rimmele P, Cohain A, Mecham B, Randolph GJ, Nabel EG, Hajjar R, Fuster V, Boehm M, Kovacic JC.Nat Commun. 2017 Feb 16;8:14710. doi: 10.1038/ncomms14710.

Inhaled Gene Transfer for Pulmonary Circulation.Aguero J, Hadri L, Hammoudi N, Leonardson L, Hajjar RJ, Ishikawa K.Methods Mol Biol. 2017;1521:339-349.

2016

Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability.Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, d’Escamard V, Li JR, Hadri L, Fujitani K, Moreno PR, Benard L, Rimmele P, Cohain A, Mecham B, Randolph GJ, Nabel EG, Hajjar R, Fuster V, Boehm M, Kovacic JC. Nat Commun. 2016 Jun 24;7:11853. doi: 10.1038/ncomms11853.

Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.Aguero J, Ishikawa K, Hadri L, Santos-Gallego CG, Fish KM, Kohlbrenner E, Hammoudi N, Kho C, Lee A, Ibáñez B, García-Alvarez A, Zsebo K, Maron BA, Plataki M, Fuster V, Leopold JA, Hajjar RJ.J Am Coll Cardiol. 2016 May 3;67(17):2032-46. doi: 10.1016/j.jacc.2016.02.049.

2015

Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension.Claude C, Mougenot N, Bechaux J, Hadri L, Brockschnieder D, Clergue M, Atassi F, Lompré AM, Hulot JS.Mol Ther Methods Clin Dev. 2015 Feb 4;2:14065. doi: 10.1038/mtm.2014.65. eCollection 2015.

Combination proximal pulmonary artery coiling and distal embolization induces chronic elevations in pulmonary artery pressure in Swine.Aguero J, Ishikawa K, Fish KM, Hammoudi N, Hadri L, Garcia-Alvarez A, Ibanez B, Fuster V, Hajjar RJ, Leopold JA.PLoS One. 2015 Apr 29;10(4):e0124526. doi: 10.1371/journal.pone.0124526. eCollection 2015.

2014

Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.Aguero J, Ishikawa K, Hadri L, Santos-Gallego C, Fish K, Hammoudi N, Chaanine A, Torquato S, Naim C, Ibanez B, Pereda D, García-Alvarez A, Fuster V, Sengupta PP, Leopold JA, Hajjar RJ.Am J Physiol Heart Circ Physiol. 2014 Oct 15;307(8):H1204-15. doi: 10.1152/ajpheart.00246.2014. Epub 2014 Aug 22.

Synergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca2+ -ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cells.Lipskaia L, Bobe R, Chen J, Turnbull IC, Lopez JJ, Merlet E, Jeong D, Karakikes I, Ross AS, Liang L, Mougenot N, Atassi F, Lompré AM, Tarzami ST, Kovacic JC, Kranias E, Hajjar RJ, Hadri L.Circulation. 2014 Feb 18;129(7):773-85. doi: 10.1161/CIRCULATIONAHA.113.002565. Epub 2013 Nov 18.

2013

Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.Lipskaia L, Hadri L, Lopez JJ, Hajjar RJ, Bobe R.Curr Vasc Pharmacol. 2013 Jul;11(4):465-79. Review.

Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Hadri L, Kratlian RG, Benard L, Maron BA, Dorfmüller P, Ladage D, Guignabert C, Ishikawa K, Aguero J, Ibanez B, Turnbull IC, Kohlbrenner E, Liang L, Zsebo K, Humbert M, Hulot JS, Kawase Y, Hajjar RJ, Leopold JA.Circulation. 2013 Jul 30;128(5):512-23. doi: 10.1161/CIRCULATIONAHA.113.001585. Epub 2013 Jun 26.

SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery. Lipskaia L, Hadri L, Le Prince P, Esposito B, Atassi F, Liang L, Glorian M, Limon I, Lompre AM, Lehoux S, Hajjar RJ. Gene Ther. 2013 Apr;20(4):396-406. doi: 10.1038/gt.2012.50.

AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Fish KM, Ladage D, Kawase Y, Karakikes I, Jeong D, Ly H, Ishikawa K, Hadri L, Tilemann L, Muller-Ehmsen J, Samulski RJ, Kranias EG, Hajjar RJ.Circ Heart Fail. 2013 Mar;6(2):310-7. doi: 10.1161/CIRCHEARTFAILURE.112.971325.

 A calcium-sensitive promoter construct for gene therapy. Merlet E, Lipskaia L, Marchand A, Hadri L, Mougenot N, Atassi F, Liang L, Hatem SN, Hajjar RJ, Lompré AM. Gene Ther. 2013 Mar;20(3):248-54. doi: 10.1038/gt.2012.30. Epub 2012 Mar 29. PMID: 22456325

Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. Karakikes I, Hadri L, Rapti K, Ladage D, Ishikawa K, Tilemann L, Yi GH, Morel C, Gwathmey JK, Zsebo K, Weber T, Kawase Y, Hajjar RJ. Mol Ther. 2012 Mar;20(3):565-71. doi: 10.1038/mt.2011.268. Epub 2012 Jan 3. PMID: 2221501

2011

Critical role for stromal interaction molecule 1 in cardiac hypertrophy.  Hulot JS, Fauconnier J, Ramanujam D, Chaanine A, Aubart F, Sassi Y, Merkle S, Cazorla O, Ouillé A, Dupuis M, Hadri L, Jeong D, Mühlstedt S, Schmitt J, Braun A, Bénard L, Saliba Y, Laggerbauer B, Nieswandt B, Lacampagne A, Hajjar RJ, Lompré AM, Engelhardt S. Circulation. 2011 Aug 16;124(7):796-805. doi: 10.1161/CIRCULATIONAHA.111.031229. Epub 2011 Aug 1. PMID: 21810664